EGFR and neoplasm: Combinatorial treatment of cetuximab with pertuzumab (2C4; HER2 monoclonal antibody)24 or seribantumab (MM-121; HER3 monoclonal antibody)25 results in effective blocking of both EGFR and HER3 signals and potent tumor suppression.